The RAF Inhibitor Paradox Revisited

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2012 Feb 21

PMID 22340588

Citations 11

Authors

Adrienne D Cox

Channing J Der

Affiliations

Soon will be listed here.

Abstract

The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies.

Citing Articles

Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway.

Sayin A, Abali Z, Senyuz S, Cankara F, Gursoy A, Keskin O Sci Rep. 2024; 14(1):1239.

PMID: 38216592 PMC: 10786864. DOI: 10.1038/s41598-023-50913-8.

Regulation of MAPK Signaling Pathways by the Large HERC Ubiquitin Ligases.

Sala-Gaston J, Costa-Sastre L, Pedrazza L, Martinez-Martinez A, Ventura F, Rosa J Int J Mol Sci. 2023; 24(5).

PMID: 36902336 PMC: 10003351. DOI: 10.3390/ijms24054906.

Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.

Whiteaker J, Sharma K, Hoffman M, Kuhn E, Zhao L, Cocco A Cell Rep Methods. 2021; 1(3).

PMID: 34671754 PMC: 8525888. DOI: 10.1016/j.crmeth.2021.100015.

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.

Kelly M, Kostyrko K, Han K, Mooney N, Jeng E, Spees K Cancer Discov. 2020; 10(12):1950-1967.

PMID: 32727735 PMC: 7710624. DOI: 10.1158/2159-8290.CD-19-1274.

The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Babagana M, Kichina J, Slabodkin H, Johnson S, Maslov A, Brown L Mol Carcinog. 2019; 59(1):5-14.

PMID: 31571292 PMC: 6908756. DOI: 10.1002/mc.23123.

References

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-7. PMC: 3143360. DOI: 10.1038/nature09626. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Leon J, Kamino H, Steinberg J, Pellicer A . H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system. Mol Cell Biol. 1988; 8(2):786-93. PMC: 363205. DOI: 10.1128/mcb.8.2.786-793.1988. View

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O . RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-15. PMC: 3724537. DOI: 10.1056/NEJMoa1105358. View

Poulikakos P, Zhang C, Bollag G, Shokat K, Rosen N . RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-30. PMC: 3178447. DOI: 10.1038/nature08902. View